33,862 Shares of Cencora, Inc. $COR Purchased by Rakuten Investment Management Inc.

Rakuten Investment Management Inc. purchased a new stake in Cencora, Inc. (NYSE:COR) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 33,862 shares of the company’s stock, valued at approximately $10,416,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. AIA Group Ltd boosted its stake in shares of Cencora by 1,344.8% in the 3rd quarter. AIA Group Ltd now owns 15,300 shares of the company’s stock valued at $4,594,000 after purchasing an additional 14,241 shares during the last quarter. Provenance Wealth Advisors LLC grew its position in shares of Cencora by 24,393.8% during the 3rd quarter. Provenance Wealth Advisors LLC now owns 3,919 shares of the company’s stock worth $1,177,000 after buying an additional 3,903 shares during the period. TrinityBridge Ltd raised its stake in shares of Cencora by 35.8% during the third quarter. TrinityBridge Ltd now owns 145,444 shares of the company’s stock worth $43,692,000 after buying an additional 38,339 shares during the last quarter. Integrity Alliance LLC. raised its stake in shares of Cencora by 4.6% during the third quarter. Integrity Alliance LLC. now owns 5,497 shares of the company’s stock worth $1,651,000 after buying an additional 240 shares during the last quarter. Finally, Integrity Advisory Solutions LLC bought a new stake in shares of Cencora during the third quarter worth approximately $207,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Cencora

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Cencora reported fiscal Q4 adjusted EPS of $4.66, above the $4.58 consensus, while revenue of $88.35 billion also topped expectations and grew 5.5% year over year. Fiscal 2026 results
• Positive Sentiment: Management forecast fiscal 2027 adjusted EPS of $19.40–$19.75, signaling continued earnings growth. Specialty-drug demand was a key contributor to results. Fiscal 2027 outlook
• Positive Sentiment: Leerink Partners raised its price target to $405 and maintained an “outperform” rating. Cencora also increased its quarterly dividend 10%, to $0.66 per share. Cencora earnings coverage
• Neutral Sentiment: Cencora is reorganizing its reporting into two segments to sharpen focus and visibility. The change may help investors assess performance, but its effect on execution remains to be seen. Organizational changes
• Negative Sentiment: Reports linked the share weakness to Cardinal Health’s earnings beat, which may have shifted investor attention toward the competitor’s results. Cencora and Cardinal Health shares

Analysts Set New Price Targets

Several brokerages recently weighed in on COR. Wall Street Zen upgraded shares of Cencora from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Evercore reaffirmed an “outperform” rating and set a $350.00 target price (up from $330.00) on shares of Cencora in a report on Thursday, August 6th. Citigroup reiterated a “buy” rating on shares of Cencora in a research report on Thursday, August 6th. Weiss Ratings upgraded shares of Cencora from a “buy (b-)” rating to a “buy (b)” rating in a research report on Tuesday, October 6th. Finally, Leerink Partners increased their price target on Cencora from $388.00 to $405.00 and gave the company an “outperform” rating in a research note on Thursday. Thirteen equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $368.73.

Insider Transactions at Cencora

In related news, EVP Elizabeth Campbell sold 11,300 shares of the business’s stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the completion of the transaction, the executive vice president owned 19,455 shares in the company, valued at approximately $6,305,754.60. The trade was a 36.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.38% of the company’s stock.

Cencora Price Performance

Shares of COR opened at $339.58 on Friday. The company has a current ratio of 0.94, a quick ratio of 0.58 and a debt-to-equity ratio of 3.01. Cencora, Inc. has a 1 year low of $244.82 and a 1 year high of $377.54. The stock has a market cap of $64.80 billion, a P/E ratio of 18.95, a price-to-earnings-growth ratio of 1.84 and a beta of 0.58. The stock’s 50-day moving average price is $324.83 and its two-hundred day moving average price is $317.36.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, November 4th. The company reported $4.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.58 by $0.08. The company had revenue of $88.35 billion during the quarter, compared to analyst estimates of $87.95 billion. Cencora had a return on equity of 110.72% and a net margin of 1.03%. The company’s revenue for the quarter was up 5.5% compared to the same quarter last year. During the same period in the previous year, the company earned $3.84 EPS. On average, equities analysts predict that Cencora, Inc. will post 19.53 earnings per share for the current year.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 30th. Investors of record on Friday, November 13th will be paid a dividend of $0.66 per share. This represents a $2.64 annualized dividend and a yield of 0.8%. The ex-dividend date of this dividend is Friday, November 13th. This is a positive change from Cencora’s previous quarterly dividend of $0.60. Cencora’s payout ratio is 14.73%.

About Cencora

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical sourcing and distribution company. It provides branded, generic and specialty pharmaceuticals, over-the-counter products and related health care supplies to pharmacies, hospitals, health systems, physician practices and other health care providers.

The company also offers services to pharmaceutical and biotechnology manufacturers, including logistics, commercialization support, market access, consulting, clinical trial support and patient assistance programs.